Beatrice Pucci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Beatrice Pucci has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Antonella Farina
Department of Experimental Medicine, Sapienza University of Rome, Policlinico Umberto I, 00181 Rome, Italy
3 shared publications - Antonio Angeloni
Interdisciplinary Department of Well-Being, Health and Environmental Sustainability (BESSA), Sapienza University of Rome, 02100 Rieti, Italy
3 shared publications - Emanuela Anastasi
Department of Experimental Medicine, Sapienza University of Rome, Policlinico Umberto I, 00181 Rome, Italy
2 shared publications - Flavia Colaiacovo
Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
2 shared publications Anna Napoli
Department of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy
1 shared publicationAurelia Gaeta
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome 00161, Italy
1 shared publication
Latest Publications
- Open Access
- 22 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 10479
Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis
Currently, ovarian cancer (OC) is a target of intense biomarkers research because of its frequent late diagnosis and poor prognosis. Serum determination of Human epididymis protein 4 (HE4) is a very important early detection test. Most interestingly, HE4 plays a unique role in OC as it has been implicated not only in OC diagnosis but also in the prognosis and recurrence of this lethal neoplasm, actually acting as a clinical biomarker. There are several evidence about the predictive power of HE4 clinically, conversely less has been described concerning its role in OC oncogenesis. Based on these considerations, the main goal of this review is to clarify the role of HE4 in OC proliferation, angiogenesis, metastatization, immune response and also in the development of targeted therapy. Through a deeper understanding of its functions as a key molecule in the oncogenetic processes underlying OC, HE4 could be possibly considered as an essential resource not only for diagnosis but also for prognosis and therapy choice.
- 22 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 10479
Open AccessRecent Insight about HE4 Role in Ovarian Cancer Oncogenesis
Currently, ovarian cancer (OC) is a target of intense biomarkers research because of its frequent late diagnosis and poor prognosis. Serum determination of Human epididymis protein 4 (HE4) is a very important early detection test. Most interestingly, HE4 plays a unique role in OC as it has been implicated not only in OC diagnosis but also in the prognosis and recurrence of this lethal neoplasm, actually acting as a clinical biomarker. There are several evidence about the predictive power of HE4 clinically, conversely less has been described concerning its role in OC oncogenesis. Based on these considerations, the main goal of this review is to clarify the role of HE4 in OC proliferation, angiogenesis, metastatization, immune response and also in the development of targeted therapy. Through a deeper understanding of its functions as a key molecule in the oncogenetic processes underlying OC, HE4 could be possibly considered as an essential resource not only for diagnosis but also for prognosis and therapy choice.
- Open Access
- 29 May 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (11) , 5994
Ovarian Cancer Biomarkers in the COVID-19 Era
Ovarian Cancer (OC) diagnosis is entrusted to CA125 and HE4. Since the latter has been found increased in COVID-19 patients, in this study, we aimed to evaluate the influence of SARS-CoV-2 infection on OC biomarkers. HE4 values above the cut-off were observed in 65% of OC patients and in 48% of SARS-CoV-2-positive patients (not oncologic patients), whereas CA125 values above the cut-off were observed in 71% of OC patients and in 11% of SARS-CoV-2 patients. Hence, by dividing the HE4 levels into quartiles, we can state that altered levels of HE4 in COVID-19 patients were mostly detectable in quartile I (151–300 pmol/L), while altered levels in OC patients were mostly clustered in quartile III (>600, pmol/L). In light of these observations, in order to better discriminate women with ovarian cancer versus those with COVID-19, we established a possible HE4 cut-off of 328 pmol/L by means of a ROC curve. These results demonstrate that the reliability of HE4 as a biomarker in ovarian cancer remains unchanged, despite COVID-19 interference; moreover, it is important for a proper diagnosis that whether the patient has a recent history of SARS-CoV-2 infection is determined.
- 29 May 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (11) , 5994
Open AccessOvarian Cancer Biomarkers in the COVID-19 Era
Ovarian Cancer (OC) diagnosis is entrusted to CA125 and HE4. Since the latter has been found increased in COVID-19 patients, in this study, we aimed to evaluate the influence of SARS-CoV-2 infection on OC biomarkers. HE4 values above the cut-off were observed in 65% of OC patients and in 48% of SARS-CoV-2-positive patients (not oncologic patients), whereas CA125 values above the cut-off were observed in 71% of OC patients and in 11% of SARS-CoV-2 patients. Hence, by dividing the HE4 levels into quartiles, we can state that altered levels of HE4 in COVID-19 patients were mostly detectable in quartile I (151–300 pmol/L), while altered levels in OC patients were mostly clustered in quartile III (>600, pmol/L). In light of these observations, in order to better discriminate women with ovarian cancer versus those with COVID-19, we established a possible HE4 cut-off of 328 pmol/L by means of a ROC curve. These results demonstrate that the reliability of HE4 as a biomarker in ovarian cancer remains unchanged, despite COVID-19 interference; moreover, it is important for a proper diagnosis that whether the patient has a recent history of SARS-CoV-2 infection is determined.
- Open Access
- 19 May 2023
- Published by Elsevier in Journal of Immunological Methods
- Vol. 518, 113486
Anti-N SARS-CoV-2 assays for evaluation of natural viral infection
- 19 May 2023
- Published by Elsevier in Journal of Immunological Methods
- Vol. 518, 113486
Open AccessAnti-N SARS-CoV-2 assays for evaluation of natural viral infection